PAMAM dendrimers of generation 4.5 loaded with curcumin interfere with α-synuclein aggregation

Q2 Pharmacology, Toxicology and Pharmaceutics
Daniela E. Igartúa , Florencia González-Lizárraga , Carolina S. Martinez , Silvia del V. Alonso , César L. Ávila , Rosana Chehín , Nadia S. Chiaramoni , M. Jimena Prieto
{"title":"PAMAM dendrimers of generation 4.5 loaded with curcumin interfere with α-synuclein aggregation","authors":"Daniela E. Igartúa ,&nbsp;Florencia González-Lizárraga ,&nbsp;Carolina S. Martinez ,&nbsp;Silvia del V. Alonso ,&nbsp;César L. Ávila ,&nbsp;Rosana Chehín ,&nbsp;Nadia S. Chiaramoni ,&nbsp;M. Jimena Prieto","doi":"10.1016/j.onano.2023.100140","DOIUrl":null,"url":null,"abstract":"<div><p>Curcumin (CUR) is a bioactive compound that has been proposed for the treatment of various neurodegenerative diseases. However, its use is limited due to its low solubility in aqueous media and chemical instability under physiological conditions. Herein, we propose a strategy to overcome these limitations by using PAMAM dendrimers of generation 4.5 (DG4.5). Using a combination of biophysical techniques together with in vitro models, we demonstrate that CUR-DG4.5 complexes: (i) increased the solubility and stability of CUR via internalization into dendrimer's pockets and interaction with terminal carboxylic groups; (ii) showed in vitro biocompatibility and increased CUR uptake; (iii) presented DPPH radical scavenging activity and in vitro inhibition of H<sub>2</sub>O<sub>2</sub>-induced stress; and (iv) interfere with α-synuclein aggregation. In conclusion, this work lays the foundation to use curcumin-loaded PAMAM dendrimers of generation 4.5 as nanodrugs capable of reducing oxidative stress and inhibiting α-synuclein aggregation to treat synucleinopathies.</p></div>","PeriodicalId":37785,"journal":{"name":"OpenNano","volume":"11 ","pages":"Article 100140"},"PeriodicalIF":0.0000,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"OpenNano","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2352952023000191","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 2

Abstract

Curcumin (CUR) is a bioactive compound that has been proposed for the treatment of various neurodegenerative diseases. However, its use is limited due to its low solubility in aqueous media and chemical instability under physiological conditions. Herein, we propose a strategy to overcome these limitations by using PAMAM dendrimers of generation 4.5 (DG4.5). Using a combination of biophysical techniques together with in vitro models, we demonstrate that CUR-DG4.5 complexes: (i) increased the solubility and stability of CUR via internalization into dendrimer's pockets and interaction with terminal carboxylic groups; (ii) showed in vitro biocompatibility and increased CUR uptake; (iii) presented DPPH radical scavenging activity and in vitro inhibition of H2O2-induced stress; and (iv) interfere with α-synuclein aggregation. In conclusion, this work lays the foundation to use curcumin-loaded PAMAM dendrimers of generation 4.5 as nanodrugs capable of reducing oxidative stress and inhibiting α-synuclein aggregation to treat synucleinopathies.

载姜黄素的第4.5代PAMAM树状大分子干扰α-突触核蛋白聚集
姜黄素(Curcumin, CUR)是一种生物活性化合物,已被提出用于治疗各种神经退行性疾病。然而,由于其在水介质中的溶解度低和生理条件下的化学不稳定性,其使用受到限制。在此,我们提出了一种通过使用第4.5代PAMAM树状大分子(DG4.5)来克服这些限制的策略。结合生物物理技术和体外模型,我们证明了CUR- dg4.5配合物:(i)通过内化到树状大分子的袋和与末端羧基的相互作用,增加了CUR的溶解度和稳定性;(ii)显示出体外生物相容性和增加的CUR摄取;(iii)具有DPPH自由基清除活性和体外抑制h2o2诱导的应激;(4)干扰α-突触核蛋白聚集。综上所述,本研究为利用第4.5代姜黄素负载的PAMAM树状大分子作为能够降低氧化应激和抑制α-突触核蛋白聚集的纳米药物治疗突触核蛋白病奠定了基础。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
OpenNano
OpenNano Medicine-Pharmacology (medical)
CiteScore
4.10
自引率
0.00%
发文量
63
审稿时长
50 days
期刊介绍: OpenNano is an internationally peer-reviewed and open access journal publishing high-quality review articles and original research papers on the burgeoning area of nanopharmaceutics and nanosized delivery systems for drugs, genes, and imaging agents. The Journal publishes basic, translational and clinical research as well as methodological papers and aims to bring together chemists, biochemists, cell biologists, material scientists, pharmaceutical scientists, pharmacologists, clinicians and all others working in this exciting and challenging area.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信